Geelong Gastro | Publications
16310
page-template-default,page,page-id-16310,page-child,parent-pageid-16244,ajax_fade,page_not_loaded,boxed,,qode-child-theme-ver-1.0.0,qode-theme-ver-13.6,qode-theme-bridge,disabled_footer_top,wpb-js-composer js-comp-ver-5.4.5,vc_responsive
 

Publications

Vasudevan A, Beswick L, Friedman AB, Moltzen A, Haridy J, Raghunath A, Sparrow MP, van Langenberg DR. Low dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in IBD. Digestive and Liver Disease 2018 S1590-8658 (18) 30177-4 (epub ahead of print)

Beswick L, Rosella O, Rosella G, Headon B, Sparrow MP, Gibson PR, van Langenberg DR. Exploration of predictive markers of early Infliximab response in acute severe colitis: A prospective pilot study. Journal of Crohns Colitis 2018; 12(3): 289-297.

Ward MG, Thwaites P, Beswick L, Hogg J, Rosella G, van Langenberg DR, Reynolds J, Gibson PR, Sparrow MP. Intra-individual variability in adalimumab drug levels within and across cycles in patients with Crohn’s disease. Alimentary Pharmacology and Therapeutics 2017; 45 (8): 1135-1145.

Beswick L, Ye B, van Langenberg DR. Towards a management algorithm for the management of CMV in patients presenting with colitis. Inflammatory Bowel Diseases 2016 Dec; 22(12):2966-2976.

Studd C, Cameron G. Beswick L, Knight R, Hair C, McNeil J, Desmond P, Wilson J, Connell W, Bell S. Never underestimate inflammatory bowel disease: High prevalence rates and confirmation of high incidence rates in Australlia. Journal of Gastroenterology and Hepatology 2016; 31(1): 81-6.

Andrews J, Costello SP, Agarwal AK, Bampton P, Beswick L, Connor S, Ghaly S, O’Connor S, Pudipeddi A, Sechi A, Sparrow M, Walsh AJ. Conflict of interest: real and perceived – a more mature consideration is needed. Internal Medicine Journal 2016; 46 (3): 377-9.

Costello SP, Ghaly S, Beswick L, Pudipeddi A, Agarwal A, Sechi AJ, O’Connor S, Connor SJ, Sparrow MP, Bampton P, Walsh AJ, Andrews JM. Compassionate access anti-TNF therapy for ulcerative colitis in Australia: The benefits to patients. Internal Medical Journal 2015; 45 (6): 659-666.

Beswick L, Kemp W. Gastrointestinal Disease. In: Symons J, Myles P, Mehra R, Ball C, editors. Perioperative medicine for the junior clinician. 1st ed.: Wiley-Blackwell; 2015.

Beswick L, Kemp W. Hepatic Disease. In: Symons J, Myles P, Mehra R, Ball C, editors. Perioperative medicine for the junior clinician. 1st ed.: Wiley-Blackwell; 2015

Beswick L, Friedman AB, Sparrow MP. The role of thiopurine metabolite monitoring in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2014; 8 (4): 383-392.

Ghaly S, Costello S, Beswick L, Pudipeddi A, Agarwal A, Sechi A, Antoniades S, Headon B, Connor S, Lawrance IC, Saprrow MP, Walsh AJ, Andrew JM. Dose tailoring of anti TNF-α therapy delivers useful clinical efficacy in Crohn’s Disease patients experiencing loss of response. Internal Medicine Journal 2014; 45 (2): 170- 177.

Beswick L, Ting A, Macrae F, Dowling D, Hair C. Divergent understanding of health professionals regarding correct subsequent management of an asymptomatic patient with a positive faecal occult blood test and negative colonoscopy with resultant cost implications. Internal Medical Journal 2014; 44 (12): 1264-1265.

Beswick L, Hair C, Dowling D. Tolerance of 6-mercaptopurine in patients with inflammatory bowel disease after azathioprine related pancreatitis. Alimentary Pharmacology & Therapeutics 2013; 37 (1); 162.

Adler NR, Biddle M, Beswick L, Hair C, Allen B, Graves S, Islam A, Watson JP. Hepatitis C virus heterogeneity: lipoprotein and immunoglobulin binding and clinical status. J Clin Exp Hepatol. 2013; 3 (4): 362-363.

Keady S, Beswick L, Read G, Sutcliffe A. Does Multi-Specialist Prescribing of Analgesics in Children Promote Errors? Pharmacy in Practice 2004; 15 (2): 84-86.